Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksC4x Discry Hdgs Regulatory News (C4XD)

Share Price Information for C4x Discry Hdgs (C4XD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.425
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.25 (2.688%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 9.425
C4XD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

3 Apr 2017 17:22

RNS Number : 4402B
C4X Discovery Holdings PLC
03 April 2017
 

 

For filings with the FCA include the annex

For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

C4X Discovery Holdings Plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

X

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

THE AQUARIUS IV FUND LLP

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

03 April 2017

6. Date on which issuer notified:

03 April 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

11%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

 

Ordinary Shares

GB00BQQ2RV18

4,864,375

4,864,375

4,864,375

4,864,375

10.66%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

4,864,375

10.66%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

DUNCAN PEYTON

15. Contact telephone number:

07879 408000

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLLFFRSIIVIID
Date   Source Headline
23rd Apr 20243:35 pmRNSHolding(s) in Company
19th Apr 20246:00 pmRNSC4X Discovery Holdings
15th Apr 202412:37 pmRNSResult of General Meeting
9th Apr 202410:58 amRNSDirector/PDMR Share Purchases
27th Mar 20247:00 amRNSProposed Voluntary Delisting
27th Mar 20247:00 amRNSInterim results
23rd Jan 20241:57 pmRNSResult of AGM
18th Jan 20247:00 amRNSBoard Update
4th Jan 20242:45 pmRNSHolding(s) in Company
3rd Jan 20247:00 amRNSAstraZeneca $11m milestone payment to C4XD
18th Dec 20233:31 pmRNSPosting of 2023 Annual Report and Notice of AGM
14th Dec 20237:00 amRNSFull Year Results
7th Dec 20237:00 amRNSNotice of Results
5th Oct 20232:35 pmRNSHolding(s) in Company
2nd Oct 202312:36 pmRNSBlock listing Interim Review
29th Sep 202311:14 amRNSGrant of Options and Directors Dealing
28th Sep 20233:52 pmRNSHolding(s) in Company
1st Sep 20237:00 amRNSTotal Voting Rights
18th Aug 202312:45 pmRNSExercise of Options, Issue of Equity and TVR
1st Aug 20237:00 amRNSDivestment of Orexin-1 to Indivior for £15.95m
20th Jun 20237:00 amRNSC4X Discovery Holdings plc: Board Change
1st Jun 20237:00 amRNSMALT-1 Inhibitor Programme Update
26th Apr 20237:00 amRNSHalf Year Results
19th Apr 20237:00 amRNSNotice of Results
8th Mar 20232:49 pmRNSBlock Listing Interim Review
22nd Feb 20237:00 amRNSC4XD and Garvan Institute collaboration
24th Jan 202311:47 amRNSResult of AGM
19th Jan 20237:00 amRNSMALT-1 Inhibitor Programme Update
10th Jan 20237:00 amRNSNick Ray Appointed as Chief Scientific Officer
19th Dec 20224:52 pmRNSPosting of 2022 Annual Report and Notice of AGM
15th Dec 20227:00 amRNSFull Year Results
28th Nov 20222:31 pmEQSC4X Discovery signs potential $402mln deal
28th Nov 20229:00 amRNSNotice of Final Results
28th Nov 20227:00 amRNSC4XD Agreement with AstraZeneca
1st Nov 20222:03 pmRNSExercise of Options, Issue of Equity and TVR
20th Oct 20227:00 amRNSC4XD and HitGen to collaborate in inflammation
4th Oct 20222:56 pmRNSHolding(s) in Company
22nd Sep 20224:40 pmRNSSecond Price Monitoring Extn
22nd Sep 20224:35 pmRNSPrice Monitoring Extension
31st Aug 202211:10 amRNSHolding(s) in Company
17th Aug 20224:06 pmRNSHolding(s) in Company
17th Aug 20223:43 pmRNSHolding(s) in Company
16th Aug 20222:17 pmRNSHolding(s) in Company
11th Aug 202212:43 pmRNSResult of Placing to Raise £5.7 million
11th Aug 20227:00 amRNSProposed Placing to Raise Up To £5.7 million
2nd Aug 20227:00 amRNSBusiness Update
1st Aug 20223:09 pmRNSBlock Listing Interim Review
6th Jul 20227:00 amRNSC4X Discovery receives Sanofi milestone payment
28th Jun 20225:46 pmRNSAIM Rule 17 Schedule 2(g) Update
28th Apr 20227:00 amRNSHalf Year Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.